1. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003. 167:603–662.
2. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998. 53:536–548.
3. World Health Organization. Treatment of tuberculosis: guidelines for national tuberculosis programme. 2003. 3rd ed.
4. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am. 1993. 77:1253–1262.
5. Korea Academy of Tuberculosis and Respiratory Disease. Guidelines for the management of pulmonary tuberculosis, 1997. Tuberc Respir Dis. 1997. 47:1447–1453.
6. Korea Center for Disease Control and Prevention. Guidelines for the management of tuberculosis. 2004.
7. Lee HS, Song HS, Lee HK, Kim KH, Chung HS, Kim CK, et al. Isoniazid metabolism and its clinical implications in Koreans. Tuberc Respir Dis. 1962. 12:22–37.
8. Harris HW, Knight PA, Selin MJ. Comparisons of isoniazid concentrations in the blood of people of Japanes and European descent. Am Rev Tuberc. 1958. 78:944–948.
9. Armstrong AR, Peart HE. A comparison between the behavior of the Eskimos and non-Eskimos to the administration of INH. Am Rev Resp Dis. 1960. 81:588–594.
10. Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the teatment of pulmonary tuberculosis. Tubercle. 1984. 65:211–227.
11. Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol. 1986. 30:335–340.
12. Chung MP, Kim HC, Suh GY, Park JW, Kim H, Kwon OJ, et al. Pharmacokinetic study of isoniazid and rifampicin in healthy Korean volunteers. Tuberc Respir Dis. 1997. 44:479–492.
13. Ahn SJ, Park SJ, Kang KW, Suh GY, Chung MP, Kim H, et al. Pharmacokinetic profiles of isoniazid and rifampicin in Korean tuberculosis patients. Tuberc Respir Dis. 1999. 47:442–450.
14. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA. 1996. 276:1229–1235.
15. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993. 329:784–791.